Physician scientist, specialized in ophthalmology ( retina, immunology and glaucoma) with experience in phase 2-3 clinical trials, pharmacovigilance.
Seven years of experience in eye biomechanics with special emphasis in the application of finite element analysis, computational mathematics and artificial intelligence to develop a virtual biomechanical and optical model of the eye with applications to surgery and soft testing of new compounds/ delivery systems in glaucoma.
Clinical research in AMD, uveitis (evaluated the link between light exposure and breakdown of the blood-ocular barrier with the aim to modulate inflammatory cascades via filtering specific spectra), and anterior segment surgery .
Since 2007 work as consultant for QLT Inc. as Director Clinical Research in the areas of retina and glaucoma and in pharmacovigilance. Since Oct 10, 2010 work as Associate Medical Director at Abbott Labs, Abbott Park, IL until July 2013. Since June 2012 Member of the Board of the American Physician Scientists Association. Since July 2013 until May 2014 he was DIrector Global Medical Development at Allergan, Inc. Since May 5, 2014 VP, Clinical Science at XOMA Corp.
Specialties: Ophthalmology- Retina, immunology, glaucoma. Start-up in medical devices. Clinical trials phases 1-3. Pharmacovigilance. Multidisciplinary teams: computational mathematics, engineering, biomaterials, biosensors, laser interferometry, artificial intelligence, evolutionary modelling. Scientific assessment of emerging drugs for ophthalmology. Ophthalmic, immunology drug development.